In Fruit Flies, MicroRNA Protects Synapses Against Excitotoxicity
Loss of the microRNA leads to glutamate toxicity and neurodegeneration.
6404 RESULTS
Sort By:
Loss of the microRNA leads to glutamate toxicity and neurodegeneration.
Data come tumbling in as more people are getting scans with the first widely used tau PET tracer. Scientists at HAI were pleased by how closely degeneration and symptoms match up in Alzheimer’s.
Early data suggest that the T807/AV1451 signal relates to cerebrospinal biomarkers of Alzheimer’s, intensifies by up to 10 percent a year, and might nail diagnoses beyond typical AD.
Autoradiography confirms that T807/AV1451 binds tau but not TDP-43. Even so, some say the tracer will benefit from more technical work to ensure it will measure small changes robustly in multicenter settings.
Keystone Symposia Meeting, Part 1—Alzheimer’s Disease: Genes, Cellular Pathways and Therapies Keystone Symposia Meeting, Part 2—Genetics and Epidemiology of AD Keystone Symposia Meeting, Part 3—Amyloid Precursor Protein Function Keystone Symposia Meeting,
An APP variant reported to stave off Alzheimer’s disease occurs in about one in 6,500 Americans.
Neuroinflammation Field Grapples With Complexity at Keystone Symposia Nature Versus Nurture: What Gives Microglia Their Identity? Microglia in Disease: Innocent Bystanders, or Agents of Destruction? United in Confusion: TREM2 Puzzles Researchers in Taos C
A TMEM106B variant widely influences the formation of TDP-43 inclusions, even in people without noticeable signs of neurodegeneration.
Researchers strongly agree that brain banks are indispensable for important discoveries in neurodegenerative disease, but funding shortfalls now threaten to stall the pace of progress.
Worldwide, brain banks are combining their holdings into large databases in an effort to better support neurodegenerative disease research.
Did you know? The NACC’s brain tissue comes with extensive clinical and cognitive data, enabling in-depth studies.
Researchers at a recent Keystone symposium compared the properties of microglia with those of other macrophages in the body. The cells acquire their unique personalities through both their origins and their present environment.
Researchers at Keystone attempted to distinguish microglia from other macrophages in the body, both in form and function, and monitor the way each behaves during disease.
Researchers sequenced the exomes of nearly 3,000 people with ALS to identify the new gene.
At the first NIH summit since the National Plan to Address Alzheimer’s was implemented back in 2012, scientists discussed progress made and put forth a new set of goals.